FDA Warns Calibrate IV Hydration Over Stem Cell and Exosome Claims
The FDA has sent a warning letter to Calibrate IV Hydration over website claims promoting umbilical cord derived and exosome products for disease-related uses. The agency said the products are being marketed as treatments that can affect the structure or function of the body and therefore fall within the definition of drugs and biological products under federal law. Because no approved biologics license application is in effect, the products are being sold without the regulatory clearance required for interstate commerce.
The letter lands in a particularly sensitive corner of regenerative medicine. Stem cell and exosome therapies have drawn intense consumer interest because they are often presented as biologically advanced, minimally invasive, and broadly restorative. In practice, those promotional claims can place companies squarely inside the FDA’s drug and biologics framework when the language moves from wellness to diagnosis, treatment, repair, inflammation control, or disease prevention.
Promotional Language Moved the Products Into Drug Territory
FDA inspectors reviewed Calibrate IV Hydration’s website, including product pages for stem cell IV treatment, exosome IV treatment, and combination packages. The pages used disease-oriented language across multiple body systems. For the stem cell IV treatment, the site claimed support for neurological function, immune balance, orthopedic recovery, endocrine health, respiratory function, and skin regeneration. The exosome page described “advanced cellular communication,” “tissue support and repair,” and “inflammation balance,” including reference to joint discomfort and inflammatory concerns.
One sentence in the warning letter carries unusual weight for clinicians reading the case. The agency said the products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans, or intended to affect the structure or function of the body. That language is the dividing line between a marketing narrative and a regulated therapeutic product. Once a company claims relief of arthritis pain, damaged tissue, inflammation, or hip pain, the agency can treat the product as more than a laboratory-derived wellness infusion.
The combination package page raised the same concerns with even broader promises. It described synergy between stem cells and exosomes for cellular communication, tissue regeneration, inflammation management, immune support, hormonal balance, and skin anti-aging. The FDA viewed those statements as evidence of intended medical use rather than generalized wellness promotion.
Homologous Use Was Central to the Agency’s Analysis
The letter also addressed a separate regulatory issue tied to the company’s umbilical cord derived product. The FDA said the product failed to meet the criterion that human cells, tissues, or cellular or tissue-based products be intended for homologous use only if they are to remain regulated solely under the section 361 framework. Homologous use means the product must perform the same basic function in the recipient as it does in the donor tissue.
That standard is not a technicality. It is the legal mechanism that separates a tissue product used for its native structural role from one being promoted as a biologic intervention for an unrelated therapeutic purpose. Umbilical cord tissue serves as a conduit in the donor; it does not naturally function as a treatment for joint pain, arthritis pain, inflammation, damaged tissue, or hip pain. Because the product was marketed for those uses, the FDA said it no longer fit the narrower HCT/P pathway and instead required regulation as a drug and a biological product.
The agency’s position follows a familiar pattern in regenerative medicine enforcement: when the promoted use departs from the tissue’s native biological role, the product can no longer rely on the most permissive regulatory pathway. For clinicians, that distinction is more than administrative. It speaks to whether a therapy has entered the domain of premarket review, where safety, purity, and potency must be demonstrated before marketing.
Exosome Marketing Drew Added FDA Attention
Exosome products are drawing closer federal scrutiny because of prior safety concerns. The warning letter points readers to FDA’s public safety notification on exosome products, which followed multiple reports of serious adverse events in patients treated with exosome products. The current letter does not describe those events in detail, but the reference signals that the agency sees a real clinical risk when exosome therapies are deployed outside an approved development pathway.
Exosomes are small extracellular vesicles involved in intercellular signaling, a biology that has made them attractive to marketers seeking to frame them as tissue repair tools. In a regulated research setting, that biology remains investigational. In a commercial setting, claims that exosomes can support recovery, rejuvenation, inflammation balance, or tissue repair can rapidly transform a speculative platform into an illegally marketed biological product if the claims imply treatment of disease.
Enforcement Risks Now Include Seizure and Injunction
FDA said the warning letter is not an exhaustive list of deficiencies, but it clearly states the next steps if the violations are not corrected. The company was instructed to respond in writing within 15 working days and explain the specific actions already taken or planned to address the violations and prevent recurrence. If the company does not believe its products violate the FD&C Act, the PHS Act, or applicable regulations, it must provide its reasoning and supporting information.
Failure to adequately address the concerns can trigger enforcement without further notice, including seizure and injunction. For clinics and marketers in the regenerative medicine space, that is the practical consequence of overpromising on products that sit outside approved pathways. The agency is not merely objecting to wording; it is asserting that the products themselves are being sold unlawfully.
The action against Calibrate IV Hydration adds to a growing body of FDA enforcement around stem cell and exosome promotions. The message is clear in the language of the letter itself: if a product is being marketed for neurological, orthopedic, pulmonary, endocrine, immune, or inflammatory conditions without an approved biologics license application, the agency is prepared to treat it as an unapproved drug and unlicensed biologic. For patients, the risk is being sold a therapy whose clinical claims have not passed the review required to establish safety, purity, and potency.